Intellectual Property India Publishes Patent Application for 'Inhibitors Of Ptp1b / Nck1 Interaction And Methods Of Making And Using Same' Filed by Radella Pharmaceuticals Llc

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517089635 A) filed by Radella Pharmaceuticals Llc, Wilmington, U.S.A., on Sept. 19, for 'inhibitors of ptp1b / nck1 interaction and methods of making and using same.'

Inventor(s) include Delibegovic, Mirela; Dall'Angelo, Sergio; Hamer, Meghan Marie; Dekeryte, Ruta; Mcewan, Andrew Robert; and Greig, Iain Robert.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "The invention relates generally to synthetic peptides which bind NCK1. The invention further relates to methods of using the peptides for inhibiting an interaction between NCK1 and PTP1B, and for treating a disease or disorder associated with insulin resistance, including type 2 diabetes and obesity."

The patent application was internationally filed on Feb. 22, 2024, under International application No.PCT/US2024/016944.

Disclaimer: Curated by HT Syndication.